Forecasting Real-World Usage of Lecanemab for AD Treatment: An Expert Roundtable

Clinicians discuss the risks and benefits and forecast the use of lecanemab for the treatment of AD in real-world clinical settings.

Related Keywords

Baltimore ,Maryland ,United States ,Missouri ,Tennessee ,Washington ,Vanderbilt University ,Peterv Rabins ,Los Angeles ,Matthews Schrag ,Lons Schneider ,Johns Hopkins School Of Medicine ,Vanderbilt University School Of Medicine ,Keck School Of Medicine ,Drug Administration ,University Of Southern California ,Medicaid Services ,Us Center ,Richman Family ,Related Dementias ,Johns Hopkins School ,Cerebral Amyloid Angiopathy Clinic ,Vanderbilt University School ,Joy Snider ,Knight Alzheimer ,Disease Research Center Clinical Trials Unit ,Washington University School ,Saint Louis ,Della Martin Chair ,Keck School ,Southern California ,Clinical Dementia Rating ,Disease Assessment Scale Cognitive Subscale ,